BioSpace News Archive

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide Nestlé Health Science with full VOWST product and related intellectual property rights.

Zomedica Corp. today announced the presentation of research highlighting the improved diagnostic capabilities of the TRUFORMA Bulk Acoustic Wave (BAW) platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay (CLIA) platforms.

I-Mab today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer.

Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, reported its Q1 2024 financial results and provided a corporate update.

Sequana Medical NV announces data from its North American pivotal POSEIDON study of the alfapump® demonstrating significantly improved quality of life focused on ascites symptoms and physical functions compared to baseline, which is not seen in refractory ascites patients enrolled contemporaneously in the prospective NACSELD3 cohort.

Agomab Therapeutics NV announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration for AGMB-447, its inhaled, small molecule inhibitor of ALK5.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented the US subgroup analysis from the sebetralstat phase 3 KONFIDENT trial and real-world claims and patient survey data at the Eastern Allergy Conference (EAC) 2024.

Aclaris Therapeutics, Inc. today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida.

Chemomab Therapeutics Ltd. today reported that it presented two scientific posters supporting the clinical rationale for the company’s primary sclerosing cholangitis (PSC) program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy.

Syndax Pharmaceuticals today announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the Company’s highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) metastatic microsatellite stable (MSS) colorectal cancer (CRC).